Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
77 Leser
Artikel bewerten:
(0)

NSF International Expands Medical Device Consulting Services in Europe With Purchase of PROSYSTEM AG

Finanznachrichten News

Acquisition of German consulting firm diversifies NSF International's medical device service offerings and provides greater access to Europe's growing and increasingly regulated medical device industry

ANN ARBOR, Michigan and HAMBURG, Germany, Oct. 9, 2017 /PRNewswire/ -- NSF International, a global public health and safety organization, recently completed the acquisition of PROSYSTEM AG, a German medical device consulting firm specializing in regulatory affairs and clinical evaluation. As part of NSF International's global medical device consulting business, the well-respected German company will be known as PROSYSTEM, an NSF International company.

Logo - http://mma.prnewswire.com/media/567251/PROSYSTEM_Logo.jpg
Photo - http://mma.prnewswire.com/media/567553/NSF_International_Oliver_Christ.jpg

Europe's US$101 billion medical device industry is expected to grow at a rate of approximately 10 percent per year while new regulatory requirements create significant opportunities for medical device consulting firms. New EU regulations for medical devices (MDR) and in-vitro diagnostic devices (IVDR) were published in May 2017, establishing new supply chain traceability requirements, new standards for clinical evidence and more rigorous reporting and post-market surveillance requirements.

The acquisition of PROSYSTEM expands NSF International's medical device business in Europe and positions the company to meet an increasing demand for medical device consulting, education and training services in the EU. Additionally, the acquisition provides NSF's global customers with a deeper knowledge of Europe's medical device industry and its changing regulatory landscape.

The PROSYSTEM acquisition also expands NSF International's medical device service offerings by adding medical device clinical evaluation, standards engagement and software development capabilities.

"The European medical device market is the second largest in the world, so it is very important for our global clients selling products in the EU," said Elaine Messa, President of medical device consulting services at NSF International. "The talented team at PROSYSTEM will help NSF International better serve global clients while also enhancing our services to clients doing business in Europe."

Founded in 1999 by the late Dr. Jürgen Stettin and Oliver Christ, PROSYSTEM specializes in risk management, quality management, regulatory affairs and clinical evaluations for the medical device industry. The company also provides a variety of other services, including education and training, project management, usability assessments and ISO standards support services.

PROSYSTEM employs 35 people, most located in Germany, and operates offices in Germany, Switzerland, Brazil and the United States. PROSYSTEM employees will join NSF International's approximately 2,730 employees working in 33 countries around the world. The company's co-founder, Oliver Christ, will join NSF International as Executive Vice President reporting to NSF International's Elaine Messa. Randolph Stender will join NSF International and retain his current title of General Manager of PROSYSTEM.

Visit NSF's medical devices website for more information about NSF International medical device services or contact medicaldevices@nsf.org.

NSF International (nsf.org) is a global independent organization that writes standards, and tests and certifies products for the health sciences, water, food and consumer goods industries to minimize adverse health effects and protect the environment. Founded in 1944, NSF is committed to protecting human health and safety worldwide. With clients in more than 170 countries, NSF International is a Pan American Health Organization/World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Indoor Environment.

NSF International's medical device services include comprehensive consulting, training and education, and testing solutions to assist medical device companies in navigating international regulatory hurdles throughout the total product lifecycle. Beyond medical devices, NSF's health sciences services include training and education, consulting, auditing, DNA testing, certification, R&D, regulatory guidance and corporate compliance for the pharma biotech, dietary supplement and bottled water/beverage industries throughout the product lifecycle.

Media Contacts

  • United States: Thomas Frey, APR, at media@nsf.org or +1 734.214.6242
  • Europe: Howard Broadbridge at hbroadbridge@nsf.org or +44 (0) 7889 810328
NSF Logo.

Logo - http://mma.prnewswire.com/media/567283/NSF_INTERNATIONAL_LOGO.jpg

© 2017 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.